Opportunity Information: Apply for PA 09 217
Apply for PA 09 217
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "The Role of Apolipoprotein E, Lipoprotein Receptors and CNS Lipid Homeostasis in Brain Aging and Alzheimers Disease (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866 Aging Research.
- This funding opportunity was created on Jul 6, 2009 and posted on Jul 6, 2009.
- Applicants must submit their applications by Sep 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,500,000.00 to eligible and selected applicants.
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Small businesses Native American tribal organizations (other than Federally recognized tribal governments) County governments City or township governments Special district governments Independent school districts For profit organizations other than small businesses Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) State governments Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PA-09-217, titled "The Role of Apolipoprotein E, Lipoprotein Receptors and CNS Lipid Homeostasis in Brain Aging and Alzheimers Disease (R01)," supports research focused on how lipid biology in the central nervous system shapes brain aging and contributes to Alzheimers disease. The central scientific theme is understanding how apolipoprotein E (ApoE), its related lipoprotein receptors, and broader lipid homeostasis pathways influence the shift from normal aging to neurodegeneration. A major emphasis is placed on clarifying the specific mechanisms by which the ApoE e4 allele increases risk for Alzheimers disease, with the idea that more precise mechanistic knowledge will help drive the development of effective treatments, including therapies specifically designed for ApoE e4-associated disease processes.
This FOA is intentionally multidisciplinary and encourages investigators to combine expertise across fields such as neurobiology, lipid metabolism, genetics, imaging, neuropathology, and computational or systems approaches. NIH is looking for studies that span multiple levels of analysis and can be conducted in multiple species, explicitly including translation from animal models (such as mice) to human biology. In practice, that means projects might investigate molecular and cellular mechanisms (for example, lipid transport, receptor signaling, synaptic effects, myelin maintenance, inflammation, or clearance pathways related to amyloid and tau), connect those findings to circuit or systems-level brain changes, and then tie them to measurable cognitive or clinical outcomes relevant to aging and Alzheimers disease.
A strong priority within the announcement is the identification of new therapeutic targets related to lipid neurobiology. This includes targets that may be relevant not only to Alzheimers disease but also to other age-related neurodegenerative conditions where lipid dysregulation plays a role. The FOA also highlights interest in early detection and biomarker development, particularly using modern, high-resolution tools. Projects that incorporate lipidomics (comprehensive profiling of lipid species), advanced imaging modalities, and other cutting-edge technologies are encouraged, especially when those approaches can reveal early signatures of neurodegeneration or detect lipid dyshomeostasis before irreversible damage occurs. The overarching expectation is that these efforts will support both mechanistic insights and practical translational outputs, such as candidate biomarkers or intervention points.
The mechanism of support is the NIH R01 research project grant, which is typically used for mature, hypothesis-driven research programs with clearly defined aims. For Fiscal Year 2010, NIH estimated a total of $2.5 million in available funds for this FOA. Because project scope can differ widely, award sizes and project durations were expected to vary. Based on the projected budget range, NIH anticipated making roughly 4 to 7 awards in FY2010, with funding in later years dependent on congressional appropriations and NIH budget decisions.
Eligibility is broad and includes many types of domestic and international organizations. Eligible applicants include nonprofit organizations (with or without 501(c)(3) status), public and private institutions of higher education, for-profit organizations (including small businesses and other for-profits), and a range of government entities (state, county, city/township, special district governments, independent school districts), as well as public housing authorities/Indian housing authorities. The FOA also explicitly includes Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), tribal governments and tribal organizations (including some categories beyond federally recognized tribes), U.S. territories or possessions, regional organizations, and non-U.S. (foreign) entities. There is no cost sharing or matching requirement.
Administratively, the opportunity was posted July 6, 2009, with an original and current closing date of September 7, 2012, and an archive date of October 8, 2012. The sponsoring agency is the National Institutes of Health, and the activity falls under CFDA 93.866 (Aging Research). The full announcement was hosted on the NIH grants site, and NIH Office of Extramural Research (OER) provided webmaster contact points for access or linking issues.
Frequently Asked Questions (FAQs)
What is the funding opportunity number and title?
The opportunity is NIH FOA PA-09-217, titled "The Role of Apolipoprotein E, Lipoprotein Receptors and CNS Lipid Homeostasis in Brain Aging and Alzheimers Disease (R01)."
Which agency is sponsoring this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
What type of grant mechanism does this FOA use?
This FOA uses the NIH R01 research project grant mechanism.
What is the central scientific focus of this FOA?
The FOA supports research on how lipid biology in the central nervous system (CNS) shapes brain aging and contributes to Alzheimers disease, with an emphasis on apolipoprotein E (ApoE), ApoE-related lipoprotein receptors, and broader CNS lipid homeostasis pathways.
What is the main theme or big-picture question NIH wants applicants to address?
The central theme is understanding how ApoE, lipoprotein receptors, and lipid homeostasis influence the shift from normal brain aging to neurodegeneration, including Alzheimers disease.
Is there a special emphasis on the ApoE e4 allele?
Yes. A major emphasis is clarifying the specific mechanisms by which the ApoE e4 allele increases risk for Alzheimers disease, with the expectation that sharper mechanistic understanding can inform the development of effective treatments, including therapies tailored to ApoE e4-associated disease processes.
What disciplines or expertise areas does NIH encourage for this FOA?
The FOA is intentionally multidisciplinary and encourages combinations of expertise across neurobiology, lipid metabolism, genetics, imaging, neuropathology, and computational or systems approaches.
Does NIH encourage projects that integrate multiple levels of analysis?
Yes. NIH is looking for studies that can span multiple levels, such as molecular and cellular mechanisms (for example, lipid transport, receptor signaling, synaptic effects, myelin maintenance, inflammation, or clearance pathways related to amyloid and tau), connect those findings to circuit- or systems-level brain changes, and tie them to measurable cognitive or clinical outcomes relevant to aging and Alzheimers disease.
Are animal models and cross-species studies allowed?
Yes. The FOA explicitly includes translation from animal models (such as mice) to human biology and supports studies conducted in multiple species.
Is translation to human biology encouraged?
Yes. Translation from animal models to human biology is explicitly included as part of the FOA's expectations.
What kinds of biological processes or pathways are highlighted as examples of relevant research areas?
Examples mentioned include lipid transport, receptor signaling, synaptic effects, myelin maintenance, inflammation, and clearance pathways related to amyloid and tau, as long as they are connected to ApoE/lipoprotein receptors/CNS lipid homeostasis in brain aging and Alzheimers disease.
Is identifying therapeutic targets a priority?
Yes. A strong priority is the identification of new therapeutic targets related to lipid neurobiology, including targets relevant to Alzheimers disease and potentially other age-related neurodegenerative conditions where lipid dysregulation plays a role.
Does the FOA include interest in early detection or biomarker development?
Yes. The FOA highlights interest in early detection and biomarker development, particularly using modern, high-resolution tools that can reveal early signatures of neurodegeneration or detect lipid dyshomeostasis before irreversible damage occurs.
Are lipidomics and advanced imaging approaches encouraged?
Yes. Projects that incorporate lipidomics (comprehensive profiling of lipid species), advanced imaging modalities, and other cutting-edge technologies are encouraged, especially when these approaches support early detection, biomarker development, or mechanistic insight.
What kinds of outputs does NIH expect from funded projects?
The FOA indicates an overarching expectation of both mechanistic insights and practical translational outputs, such as candidate biomarkers or intervention points (therapeutic targets).
What is the CFDA number associated with this opportunity?
The activity falls under CFDA 93.866 (Aging Research).
How much total funding was NIH expecting to have available?
For Fiscal Year 2010, NIH estimated a total of $2.5 million in available funds for this FOA.
How many awards did NIH anticipate making?
Based on the projected budget range, NIH anticipated making roughly 4 to 7 awards in FY2010.
Will award sizes and project durations be the same for all grantees?
No. The FOA notes that because project scope can differ widely, award sizes and project durations were expected to vary.
Is future-year funding guaranteed?
No. Funding in later years was expected to depend on congressional appropriations and NIH budget decisions.
Who is eligible to apply?
Eligibility is broad and includes domestic and international organizations, including nonprofit organizations (with or without 501(c)(3) status), public and private institutions of higher education, for-profit organizations (including small businesses and other for-profits), and many government entities.
Are foreign (non-U.S.) entities eligible to apply?
Yes. The FOA explicitly includes non-U.S. (foreign) entities among eligible applicants.
Are for-profit organizations eligible?
Yes. For-profit organizations, including small businesses and other for-profits, are listed as eligible applicants.
Are government entities eligible?
Yes. Eligible government entities include state, county, city/township, special district governments, independent school districts, and public housing authorities/Indian housing authorities, among others.
Are tribal governments and tribal organizations eligible?
Yes. The FOA explicitly includes tribal governments and tribal organizations, including some categories beyond federally recognized tribes.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are included in the eligibility list.
Does the FOA highlight eligibility for institutions serving specific populations?
Yes. It explicitly includes Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
When was this opportunity posted?
The opportunity was posted on July 6, 2009.
What was the closing date for submissions?
The original and current closing date listed is September 7, 2012.
When was the opportunity archived?
The archive date is October 8, 2012.
Where was the full announcement hosted?
The full announcement was hosted on the NIH grants site.
Who provided contact points for access or linking issues?
The NIH Office of Extramural Research (OER) provided webmaster contact points for access or linking issues.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: Fish Distribution and Habitat Use Delineation within the Boundary of the Glennallen Field Office, Alaska
Previous opportunity: Montana Education and Weed Awareness
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 217
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 217) also looked into and applied for these:
| Funding Opportunity |
|---|
| Proteomics in Auditory Developmental and Disease Processes (R01) Apply for PA 09 228 Funding Number: PA 09 228 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Oral Mucosal Vaccination against HIV Infection (R01) Apply for RFA DE 10 001 Funding Number: RFA DE 10 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Public Health Emergency Response (PHER) Apply for CDC RFA TP09 902 H1N109 Funding Number: CDC RFA TP09 902 H1N109 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Support for Implementation and Expansion of HIV Prevention, Care and Treatment Services at National Teaching and Referral Hospitals (NT RHs) As Centers of Excellence in the Republic of Kenya Under The President s Emergency Fund for AIDS Relief (PEPF Apply for CDC RFA PS10 1004 Funding Number: CDC RFA PS10 1004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
| Strengthening Health Outcomes through the Private Sector (SHOPS) Apply for M OAA GH POP 09 0709 Funding Number: M OAA GH POP 09 0709 Agency: Agency for International Development Category: Health Funding Amount: $200,000,000 |
| Grants to States for Loan Repayment Apply for HRSA 09 228 Funding Number: HRSA 09 228 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| NHLBI Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral MD/PhD Fellows (F30) Apply for PA 09 232 Funding Number: PA 09 232 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAID Partnerships with Product Development Public Private Partnerships (R01) Apply for RFA AI 09 034 Funding Number: RFA AI 09 034 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of New Technologies Needed for Studying the Human Microbiome (R01) Apply for RFA RM 09 008 Funding Number: RFA RM 09 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of New Technologies Needed for Studying the Human Microbiome (R21) Apply for RFA RM 09 009 Funding Number: RFA RM 09 009 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Epidemiological MCH/SPH Institute Apply for HRSA 09 265 Funding Number: HRSA 09 265 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Short Term Research Education Program to Increase Diversity in Health Related Research (R25) Apply for RFA HL 10 013 Funding Number: RFA HL 10 013 Agency: National Institutes of Health Category: Health Funding Amount: $106,250 |
| Revolutionary Genome Sequencing Technologies The 1000 Genome (R01) Apply for RFA HG 09 011 Funding Number: RFA HG 09 011 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Revolutionary Genome Sequencing Technologies The 1000 Genome (R21) Apply for RFA HG 09 012 Funding Number: RFA HG 09 012 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Revolutionary Genome Sequencing Technologies The 1000 Genome (SBIR R43/R44) Apply for RFA HG 09 013 Funding Number: RFA HG 09 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Awards to Support Research on the Biology of Aging in Invertebrates (R01) Apply for RFA AG 10 004 Funding Number: RFA AG 10 004 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| AHRQ Grants for Health Services Research Dissertation Program (R36) Apply for PAR 09 212 Funding Number: PAR 09 212 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $40,000 |
| Increasing Immunization Rates through Healthcare Provider Partnerships Apply for CDC RFA IP09 903 Funding Number: CDC RFA IP09 903 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Childhood Immunization Support Project Apply for CDC RFA IP09 904 Funding Number: CDC RFA IP09 904 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Rural Health Network Development Planning Grant Program Apply for HRSA 10 020 Funding Number: HRSA 10 020 Agency: Health Resources and Services Administration Category: Health Funding Amount: $85,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 217", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.